STEP 1 Trial Explained: Semaglutide 2.4 mg for Obesity in 2 Minutes
Can once-weekly semaglutide produce meaningful weight loss in adults with obesity?
In this 2-minute evidence brief, we break down the STEP 1 ...
Can once-weekly semaglutide produce meaningful weight loss in adults with obesity?
In this 2-minute evidence brief, we break down the STEP 1 ...
This week on Hormone Insight: the fallout from the ADA 2026 Scientific Sessions, where retatrutide — a triple GIP/GLP-1/glucagon agonist — delivere...
This week on This Week in Diabetes & Endocrinology, from Hormone Insight: the
first large phase 3 trial of an oral GLP-1, orforglipron, in ad...
Oral Ozempic Launch, Semaglutide for Alcohol Use Disorder (Lancet RCT), and Canada’s First Generic Semaglutide | Week Ending May 8, 2026
...
This episode reviews key diabetes/endocrinology updates for the week ending May 1, 2026: FDA clearance of Tandem Control-IQ Plus automat...
The Week in Diabetes & Endocrinology — Episode 004 | April 24, 2026
From Hormone Insight (hormoneinsight.com)
Six stories th...
The Week in Diabetes & Endocrinology — Episode 003 | April 17, 2026
From Hormone Insight (hormoneinsight.com)
Six stories th...
The Week in Diabetes & Endocrinology — Episode 001 | April 3, 2026
From Hormone Insight (hormoneinsight.com)
Six stories thi...
In this episode of Hormone Insight, we examine a 2024 post hoc analysis published in Diabetes Care.